COGT

Cogent Biosciences, Inc. [COGT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

COGT Stock Summary

Top COGT Correlated Resources

COGT

Top 10 Correlated ETFs

COGT

Top 10 Correlated Stocks

COGT

In the News

COGT Financial details

Company Rating
-
Market Cap
676.47M
Income
-187.76M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
164
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-2.68
Forward P/E
-
PEG
-7.57
P/S
-
P/B
1.49
P/C
-
P/FCF
-4.29
Quick Ratio
8.04
Current Ratio
9.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.34
EPS next Y
-
EPS next Q
-
EPS this Y
7.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-9.43%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-1.56%
-
-
-
-
SMA20
-40.44%
SMA50
-52.71%
SMA100
-53.62%
Inst Own
-
Inst Trans
-
ROA
-48%
ROE
-60%
ROC
-0.6%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.67-13.5
52W High
-66.92%
52W Low
+43.33%
RSI
33.97
Rel Volume
0.44
Avg Volume
2.19M
Volume
957.07K
Perf Week
-3.59%
Perf Month
-38.66%
Perf Quarter
-64.2%
Perf Half Y
-63.74%
-
-
-
-
Beta
-0.081
-
-
Volatility
0.25%, 1.27%
Prev Close
-1.6%
Price
4.3
Change
1.18%

Something similar

Top by Market Cap
GOOGL
0YXG.L
BRK-A
MSFT
LLY.SW
Top Correlated ETFs
LABU
BIB
HMMJ.TO
IBB
BBH
Top Correlated Stocks
DYN
CMCM
FBIOX
PROF
ALGS
Similar Market Cap
CCV-UN
0021.HK
FPAC
1645.HK
USPX

Company Profile

Healthcare Biotechnology
  • Volume Average 2.19M
  • Market Capitalization 676.47M
  • Employee 164
  • CEO Mr. Andrew R. Robbins M.B.A.
  • Headquarters Cambridge,MA,US
  • IPO Date 2018-03-29
  • Website https://www.cogentbio.com

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.